BURLINGAME, Calif., Jan. 24 /PRNewswire/ -- BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that it has entered into a collaboration agreement with Dainippon Sumitomo Pharma Co. (DSP), a global biopharmaceutical leader based in Japan. Under the collaboration, BioSeek will apply its BioMAP(R) Systems to support compound differentiation, lead development, and drug candidate selection activities for DSP’s discovery programs in the fields of inflammation and metabolic diseases.
“We are excited to be working closely with DSP, a well respected and innovative global company, and look forward to supporting their discovery efforts,” commented Michael C. Venuti, Ph.D., CEO of BioSeek. “This collaboration leverages our technology platform’s power in addressing key decision points in the discovery process, making it extremely valuable to partners such as DSP.”
“The BioMAP(R) platform represents a very compelling approach to applying human systems biology to pharmaceutical research and development,” stated Dr. Yuichi Yokoyama, Executive Director at DSP. “BioMAP(R) Systems deliver otherwise difficult-to-obtain human biological information, which will help us prioritize leads and candidates.”
CTC Laboratory Systems Corporation, a subsidiary of Itochu Techno- Solutions Corporation, assisted with the closing of this agreement.
BioMAP(R) Systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in BioSeek’s database. BioMAP profiling provides early insight into human pharmacological properties of compounds including in-depth characterization of biological drug function, on- and off-target activities, and biomarker identification.
About BioSeek
BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. BioSeek is using BioMAP(R) Systems platform for the internal discovery and development of new drug candidates in the fields of inflammation, cardiovascular diseases, autoimmune diseases, and related indications. BioSeek is also leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners’ pipelines. For more information, go to www.bioseekinc.com.
About Dainippon Sumitomo Pharma Co.
Dainnipon Sumitomo Pharma Co.'s Corporate Mission is to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide. For more information, go to http://www.ds-pharma.co.jp/english.
About CTC Laboratory Systems Corporation
CTC Laboratory Systems Corporation (Tokyo, Japan), a subsidiary of Itochu Techno-Solutions Corporation, is Japan’s leading provider of total solutions from target ID/VD to clinical trials for pharmaceuticals, and a variety of solutions for the chemical and food processing industries, as well as for life sciences research institutions. Additional information on CTCLS can be found at http://www.ctcls.co.jp.
CONTACT: Michael Venuti, Ph.D., CEO, of BioSeek, Inc., +1-650-552-0754; or
Jennifer Greenleaf of MacDougall Biomedical Communications for BioSeek,
Inc., +1-781-235-3060
Web site: http://www.bioseekinc.com/
http://www.ds-pharma.co.jp/english/
http://www.ctcls.co.jp/
